Christine McCauley - Edwards Lifesciences Corporate Resources
| EW Stock | USD 75.38 0.57 0.76% |
Executive
Christine McCauley is Corporate Resources of Edwards Lifesciences Corp
| Age | 59 |
| Address | One Edwards Way, Irvine, CA, United States, 92614 |
| Phone | 949 250 2500 |
| Web | https://www.edwards.com |
Edwards Lifesciences Management Efficiency
The company has Return on Asset (ROA) of 0.1065 % which means that for every $100 of assets, it generated a profit of $0.1065. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1914 %, which means that it produced $0.1914 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer Chaloemtiarana | Doximity | 56 | |
| Matthew Robinson | Veeva Systems Class | 50 | |
| Robert Pringle | Laboratory of | N/A | |
| Nanette Sanders | Mednax Inc | N/A | |
| Michele OConnor | Veeva Systems Class | 47 | |
| Jennifer Higgins | Guardant Health | N/A | |
| Christopher Freeman | Guardant Health | 50 | |
| Mary CPA | Cigna Corp | N/A | |
| Mary Picerno | Cigna Corp | N/A | |
| Arjan Toor | Cigna Corp | N/A | |
| Anita Graham | Laboratory of | 53 | |
| Kristine Diamond | Veeva Systems Class | 56 | |
| Matt Ruderman | Definitive Healthcare Corp | N/A | |
| Bruno Miranda | Doximity | N/A | |
| Daniel Corcoran | Mednax Inc | N/A | |
| Jamie Kates | Cigna Corp | 44 | |
| CPC MBA | Mednax Inc | N/A | |
| Jennifer JD | Doximity | 56 | |
| Craig Overpeck | Doximity | N/A | |
| Alexis Jones | Cigna Corp | N/A | |
| Brian Wagener | Veeva Systems Class | 42 | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.11 |
Edwards Lifesciences Corp Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul LaViolette, Independent Director | ||
| Larry Wood, Corporate Vice President - Transcatheter Aortic Valve Replacement | ||
| Leslie Heisz, Independent Director | ||
| Catherine Szyman, Corporate Vice President - Critical Care | ||
| Arnold Pinkston, Corporate Counsel | ||
| Arnold JD, Corporate Counsel | ||
| Steven Loranger, Independent Director | ||
| Scott Ullem, Chief Financial Officer, Corporate Vice President | ||
| Kieran Gallahue, Independent Director | ||
| Nicholas Valeriani, Independent Director | ||
| Heisz Stone, Independent Director | ||
| Mark Wilterding, Vice Relations | ||
| MD FACC, Corporate Officer | ||
| Angela Fuente, Director Engineering | ||
| Martha Marsh, Lead Independent Director | ||
| Daveen Chopra, Corporate Vice President - Surgical Structural Heart | ||
| Huimin Wang, Corporate Vice President - Japan, Asia and Pacific | ||
| JeanLuc Lemercier, Corporate Vice President - EMEA (Europe, Middle East and Africa) | ||
| Christine McCauley, Corporate Resources | ||
| William Link, Independent Director | ||
| Gary Sorsher, Senior Compliance | ||
| Ramona Sequeira, Independent Director | ||
| Bernard Zovighian, Corporate Vice President -Surgical Heart Valve Therapy | ||
| Daniel Lippis, Greater Japan | ||
| Donald Bobo, Corporate Vice President - Strategy and Corporate Development | ||
| Todd Brinton, Co Officer | ||
| Dirksen Lehman, Corporate Affairs | ||
| Finn Haley, Vice Development | ||
| Andrew Dahl, Senior Officer | ||
| Michael Mussallem, Chairman of the Board, Chief Executive Officer |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.66 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 40.38 B | ||||
| Shares Outstanding | 589.8 M | ||||
| Shares Owned By Insiders | 0.91 % | ||||
| Shares Owned By Institutions | 86.02 % | ||||
| Number Of Shares Shorted | 8.58 M | ||||
| Price To Earning | 32.77 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.